Baiyunshan Pharma
Baiyunshan Pharmaceutical is a comprehensive pharmaceutical research and development company
Baiyunshan Pharmaceutical is a comprehensive pharmaceutical research and development company, the company's business includes "Great Southern Medicine", "Great Health", "Great Business" and "Great Medical" four business segments, the main products include Quenching Thirst Pills, Angong Niuhuang Pills, Wanglaoji herbal tea, etc. In addition, the company is also engaged in health management, health care and retirement and other health industry investment.
Hecheng Co., Ltd.: the abbreviation of the company's securities is proposed to be changed to "Jianfa Hecheng"
Cellatopia Secures Nearly CNY Ten Mn in Seed Funding
EqualOcean has learned that Cellatopia(喜同生物), a biotechnology company based in Suzhou, recently announced the successful securing of nearly CNY ten million in seed funding. The funding was primarily led by Suzhou Shishangbai Venture Capital(苏州石上柏创业合伙企业) and followed by institutions such as Suzhou Nuowei Venture Investment Limited(苏州诺为创业投资有限公司).
Apr 18, 2024 01:25 PM
Haier Biomedical 'Smart Blood City Network' Lands in Brazil
Brazil, as the largest country and economy in South America, faces numerous challenges brought about by an aging population. With the country's economy continuing to grow, healthcare issues are receiving increasing attention, and the demand for medical services is rising year by year.
Apr 15, 2024 03:45 PM
Great wall holding Weishi energy completed the round a financing of RMB 900 million, and the post investment valuation exceeded RMB 4 billion
D3 Bio Completes A+ Round Financing, Accelerates Development of Product Pipeline
EqualOcean has learned that on April 8, 2024, D3 Bio(德昇济医药), a biotechnology company focused on the development and commercialization of innovative cancer and immune precision therapies, announced the successful completion of its A+ round financing led by Medicxi, a prominent European life sciences investment firm. The financing amounted to USD 62 million, with existing investor, Matrix Partners(经纬创投), also participating.
Apr 12, 2024 06:05 PM